SEARCH · Search PubMed

Results for “Tics”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources

PubMed1986

Semiology, nosology and criteria for tic disorders.

Precise description of the signs, symptoms, classification and criteria for Tic Disorder and Gilles de la Tourette Syndrome (GTS) is important to reduce heterogeneity in studies and to develop hypotheses about the pathophysiology of these disorders. Previous diagnostic categories and criteria for Tic Disorders and GTS in DSM-III and ICD-9 were derived from our study of 114 consecutive patients, questionnaire responses by 31 patients and data on 76 patients from 8 published reports. During the past 20 years we have evaluated 1490 patients for movement disorders, of whom 1210 had GTS and 137 had another tic disorder. Analysis of these data and review of the literature serve as the basis for proposed revision of the signs, symptoms, nosology and criteria for Tic Disorders and GTS.

Compulsive Behavior↗

PubMed1983

Remission of tics with lithium therapy: case report.

A patient with multiple tics and cyclothymic disorder was treated with lithium, with complete remission of the tics. Clinical, neurochemical, and physiologic studies suggest a potential role of lithium in treatment of tics. Carefully controlled therapeutic trials of lithium in tic disorders are recommended.

Adult↗

PubMed1981

[Pathogenesis and treatment of tic-type hyperkinesis in children].

Results of clinical and electrophysiological examinations of 52 children with tic-type hyperkineses are presented. Nine of them had generalized tic (Gilles de la Tourette's disease), and 43 had local forms. All the children were examined electroencephalographically; 26 children had, in addition, an electronystagmographic examination. Changes pointing to organic affections of the brain were revealed. The authors recommend that anticonvulsants be used for tic therapy. In children with generalized tic the anticonvulsants may be combined with haloperidol.

Adolescent↗

PubMed1978

Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration.

Central nervous system metabolism in six children and one adult with the syndrome of chronic multiple tics was studied by measuring the accumulation of acid metabolites of dopamine and serotonin (homovanillic acid [HVA] and 5-hydroxyindole-acetic acid [5-HIAA], respectively) in the CSF following probenecid administration. The accumulation of 5-HIAA was reduced in patients with multiple tics in contrast with other pediatric patients (N = 27). The degree of reduction in 5-HIAA relative to HVA appeared to be associated with the severity of the tic disorder. With dextroamphetamine, tic symptoms worsened, CSF HVA level decreased, and CSF 5-HIAA concentration increased. These findings suggest an association in Gilles de la Tourette's disease of reduced functioning of inhibitory serotonergic mechanisms and functional dopaminergic overactivity.

Adolescent↗

PubMed2003

Functional properties of Pfr(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors.

The functional characteristics of two putative neuropeptide FF (NPFF) antagonists, BIBP3226 and PFR(Tic)amide, on the human neuropeptide FF receptor subtype 2 (hNPFF2) were investigated. Surprisingly, PFR(Tic)amide was shown to exhibit agonist properties in the [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgammaS) binding assay. The efficacy of PFR(Tic)amide was significantly greater than that of (1DMe)Y8Fa, a stable analog of NPFF, and PFR(Tic)amide can therefore be classified as a 'super-agonist'. BIBP3226 did act as a reversible competitive antagonist on the hNPFF2 receptor. However, high concentrations of BIBP3226 also non-specifically increased [35S]GTP-gammaS binding. The usefulness of BIBP3226 as an antagonist tool on the NPFF receptor is thus limited.

Animals↗

PubMed2006

Rat NPFF(1) receptor-mediated signaling: functional comparison of neuropeptide FF (NPFF), FMRFamide and PFR(Tic)amide.

Neuropeptide FF (NPFF) participates in many physiological functions associated with opioids in the mammalian CNS. We established a pheochromocytoma PC-12 cell line clone stably expressing rat NPFF1 receptors. Both NPFF and FMRFamide activated NPFF1 receptors to couple with Gi/o protein and inhibited adenylyl cyclase activity in PC-12/rNPFF1 cells, but there were no effects on MAPKs (ERK1/2 and p38 MAPK) or PI3K/Akt pathway. FMRFamide also inhibited DARPP-32/Thr34 phosphorylation in the presence of forskolin. Similarly, PFR(Tic)amide, a 'super-agonist' of NPFF receptors, inhibited the production of cAMP and slightly decreased DARPP-32/Thr34 phosphorylation in PC-12/rNPFF1 cells. Intracerebroventricular injections of PFR(Tic)amide blocked behavioral sensitization of locomotor activity to amphetamine, and intrathecal injection of PFR(Tic)amide caused a dose-dependent antinociception in vivo in rats. Thus, "over-activation" of NPFF receptors by PFR(Tic)amide induced different bio-effects from those induced by NPFF in vivo.

Adenylyl Cyclases↗

PubMed2000

Assessment of substitution in the second pharmacophore of Dmt-Tic analogues.

The Dmt-Tic pharmacophore exhibits potent delta-opioid receptor antagonism. Analogues with substitutions in the second pharmacophore with (1, 1') or without a COOH function (2-9) were synthesized: several had high delta affinity (1', 2, 7, and 9), but exhibited low to non-selectivity toward mu receptors similar to H-Dmt-Tic-amide and H-Dmt-Tic-ol. Functional bioactivity indicated high delta antagonism (pA2 7.4-7.9) (1', 2, and 9) and modest mu agonism, pEC50 (6.1-6.3) (1', 2, 8, and 9), but with Emax values analogous to dermorphin. These Dmt-Tic analogues with mixed delta antagonist/mu agonist properties would appear to be better candidates as analgesics than pure mu agonists.

Analgesics↗

PubMed2000

Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists.

A series of Dmt-Tic analogues with substitution on the Tic aromatic ring has been synthesized and evaluated for opioid receptor affinity and activation. Incorporation of large hydrophobic groups at position 7 of Tic did not greatly alter the delta opioid receptor binding affinities of the dipeptides whereas substitution at position 6 substantially diminished their affinity. These modified Dmt-Tic peptides showed binding affinities as low as 2.5 nM with up to 500-fold selectivity for the delta versus mu opioid receptor and proved to be delta receptor antagonists.

Benzamides↗

PubMed1995

Tics and fits. The current status of Gilles de la Tourette syndrome and its relationship with epilepsy.

The Gilles de la Tourette syndrome (GTS) is a neurobehavioural disorder characterized by multiple motor and vocal tics. Accessory symptoms include coprophenomena, echophenomena and obsessive-compulsive behaviours. There is a significant genetic contribution to their aetiology. Simple tics may be mistaken for myoclonic epilepsy and complex tics for complex partial seizures. Like epilepsy, GTS is a brain disorder that leads to general disturbances in behaviour not just the cardinal symptoms (i.e. tics or seizures).

Antipsychotic Agents↗

PubMed2007

Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.

The opioid peptide TIPP (H-Tyr-Tic-Phe-Phe-OH, Tic:1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) was substituted with Dmt (2',6'-dimethyltyrosine) and a new unnatural amino acid, beta-MeCha (beta-methyl-cyclohexylalanine). This double substitution led to a new series of opioid peptides displaying subnanomolar delta antagonist activity and mu agonist or antagonist properties depending on the configuration of the beta-MeCha residue. The most promising analog, H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH was a very selective delta antagonist both in the mouse vas deferens (MVD) assay (Ke = 0.241 +/- 0.05 nM) and in radioligand binding assay (K i delta = 0.48 +/- 0.05 nM, K i mu/K i delta = 2800). The epimeric peptide H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH and the corresponding peptide amide turned out to be mixed partial mu agonist/delta antagonists in the guinea pig ileum and MVD assays. Our results constitute further examples of the influence of Dmt and beta-methyl substitution as well as C-terminal amidation on the potency, selectivity, and signal transduction properties of TIPP related peptides. Some of these compounds represent valuable pharmacological tools for opioid research.

Animals↗

PubMed2006

TiC nanocrystal formation from carburization of laser-grown Ti/O/C nanopowders for nanostructured ceramics.

Refractory carbide ceramics (TiC and ZrC) raise interest as promising materials for high-temperature applications such as structural materials for the future generation of nuclear reactors. In this context, nanostructured ceramics are expected to exhibit improved thermomechanical properties as well as better behavior under irradiation when compared to conventional materials. It is therefore necessary to synthesize carbide nanocrystals of such materials to elaborate the ceramics. We report here the formation study of TiC nanocrystals through the direct carburization of Ti/O/C nanopowders grown by laser pyrolysis. A spray of titanium tetraisopropoxide was laser pyrolyzed with ethylene as the sensitizer, leading to Ti/O/C nanopowders with various C contents controlled by the synthesis conditions. Annealing treatments performed on these nanopowders under an inert atmosphere without any C addition enabled the formation of TiC grains through the carburization of the oxide phase by free C incorporated during the synthesis. The powders were characterized by X-ray diffraction, scanning electron microscopy, and transmission electron microscopy. The final TiC grain size was about 80 nm, and the grains were monocrystalline. The influence of the free C content on the grain growth during the annealing step, together with its effects on the densification of the ceramics after sintering by high-pressure flash sintering, was examined. A 93% densification was finally achieved.

Journal Article↗

PubMed2003

The paroxysmal hemicrania-tic syndrome.

Two cases of paroxysmal hemicrania (PH) associated with trigeminal neuralgia are reviewed. The paroxysmal hemicrania component in one patient was episodic, while it was chronic in the other. Each headache type responded completely to separate treatment, highlighting the importance of recognizing this association. We review the six other cases of chronic paroxysmal hemicrania-tic (CPH-tic) reported, and suggest that the term paroxysmal hemicrania-tic syndrome (PH-tic) be used to describe this association.

Aged↗

PubMed2003

Selective delta-opioid receptor antagonist N,N(CH3)2-Dmt-Tic-OH does not reduce ethanol intake in alcohol-preferring AA rats.

We studied the effect of a novel delta-opioid receptor antagonist N,N(CH(3))(2)Dmt-Tic-OH (Me(2)-Dmt-Tic-OH) on voluntary ethanol intake in an alcohol-preferring AA (Alko, Alcohol) rat line using a 4-hour limited access paradigm. Acute injections of Me(2)-Dmt-Tic-OH (10 and 30 mg/kg, i.p.) did not reduce 1-hour or 4-hour ethanol intake. Subtype non-selective opioid receptor antagonist naltrexone [0.1 and 0.3 mg/kg, subcutaneously (s.c.)] significantly reduced 1-hour ethanol drinking but had no effect on 4-hour ethanol consumption. Locomotor stimulation induced by the delta-opioid receptor agonist Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE; 15 microg, intracerebroventricularly) was significantly attenuated by Me(2)-Dmt-Tic-OH (10 and 30 mg/kg, i.p.), which confirmed its efficacy as a delta-opioid receptor antagonist in rat brain. Our results support the idea that delta-opioid receptors do not mediate alcohol reward in AA rats.

Alcoholism↗

PubMed1993

Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome.

Concerns have been raised regarding the development of tics in some children with attention-deficit hyperactivity disorder (ADHD) receiving stimulants. Because in many patients with Tourette's syndrome (TS) the ADHD symptoms are the major source of disability, alternative nonstimulant treatments are needed. Initial reports on bupropion have suggested that it may be an effective alternative in children and adults with ADHD. The value of bupropion as an alternative treatment for patients with comorbid TS and ADHD is determined by the question of association with exacerbation of tics. The purpose of this study was to examine an apparent association with exacerbation of tics in patients with comorbid TS and ADHD. A careful retrospective analysis was conducted of clinic cases of patients who all had comorbid TS and ADHD treated with bupropion. We present four cases of children with ADHD and comorbid TS treated with bupropion in whom tics were exacerbated by this medicine. This series suggests that bupropion may not be an appropriate alternative to stimulants in the treatment of ADHD in TS.

Attention Deficit Disorder with Hyperactivity↗

PubMed1999

Tics in Tourette syndrome: new treatment options.

Tourette Syndrome is a familial neurobehavioral disorder characterized by fluctuating involuntary motor and/or vocal tics. The most commonly used medications to treat Tourette's syndrome are haloperidol, pimozide, fluphenazine, and clonidine, all of which may have considerable side effects. We enrolled 450 patients with tics/Tourette's syndrome to be treated with baclofen/botolinum toxin type A for their symptoms. Global severity of tic symptoms was rated by the Yale Global Tic Severity Scale and a quantified videotaped micro-structured analysis of tics. We found that baclofen/botolinum toxin type A are very effective, safe, and reliable in the treatment of tics/Tourette's syndrome. It is worthwhile considering this treatment approach in patients with tics/Tourette's syndrome in order to reduce or avoid the side effects of other medications. Further studies, however, are required.

Adolescent↗

PubMed2000

[Studies on properties of biofriction and wear for friction pairs of UHMWPE and Ti matrix-TiN-TiC gradient film materials].

In order to search the possible application of friction pairs of UHMWPE and Ti6Al4V-TiN-TiC etc. gradient materials to total hip joint replacements, we have prepared Ti6Al4V-TiN-TiC etc. gradient film materials by using N ion implant, d. c plasma CVD(PCVD). The properties of biological friction and wear for friction pairs of HUMWPE and Ti6Al4V-TiN-TiC etc. gradient film materials were investigated. The friction coefficient of friction paris and the wear loss of worn UHMWPE were measured; the surface morphology was observed by SEM. It has been shown that in human serum lubrication the wear loss of HUMWPE decreases with the increase in the surface hardness of its pairing ceramic film material. The pairing Ti6Al4V-TiN-TiC gradient film material possesses highest surface hardness, compared with other materials studied; UHMWPE wear loss in lowest. The wear mechanism of studied pairs has been analysed as well in the present paper.

Biocompatible Materials↗

PubMed1986

[Tics: from Itard to the neuroleptics].

When the six DSM-III (1980) diagnostic criteria are applied to the nine cases reported by Gilles de la Tourette in 1885, six of them are found to be in accordance with the diagnosis of Gilles de la Tourette's syndrome (cases nos 4, 5 and 7 do not involve vocal tics). Gilles de la Tourette deserves credit, not only for having regrouped fragmented observations into one remarkably well described clinical entity which held over time (such as Itard's observations nos 9 and 10 in 1825; the latter is the famous Marquise of D ... seen several times by Charcot and the only one which, along with no 1, appears in Gilles de la Tourette's paper), but also for having described the course of this chronic and fluctuating disease. Why Gilles de la Tourette did not use the term "tic", a term which had been in use for a long time in both veterinary and human medicine, to describe "the motor incoordination" of these patients? Did Charcot take some distance from his student's paper as early as 1885? He viewed tics as the basis of "the disease described by Gilles de la Tourette". In addition to coprolalia and echolalia, he alsa reported the existence of "mental tics". How have French neurologists and psychiatrists been able to perpetuate Brissaud's error who, contrary to Gilles de la Tourette, mentioned that the illness "can be associated with severe mental disorders which often lead to dementia"?(ABSTRACT TRUNCATED AT 250 WORDS)

France↗

PubMed1982

Treatment of tic douloureux by percutaneous retrogasserian glycerol injection.

Thirty patients with tic douloureux underwent treatment by percutaneous retrogasserian glycerol injection (PRGI). All patients had symptomatic trigeminal neuralgia refractory to medical therapy. Fifteen patients had recurrent tic after one to four prior operations. The technique was simple to perform and required no intraoperative physiological testing or short-acting barbiturate supplementation during transovale placement of a spinal needle in the trigeminal cistern of Meckel's cave. Precise placement of small volumes (0.15 to 0.35 mL) of sterile glycerol was ensured by first demonstrating the anatomy of the trigeminal cistern using metrizamide. Overall, 23 patients have remained pain free five to 12 months after treatment. Nineteen patients had no change in facial sensation after injection. Treatment by PRGI is a valid alternative therapy for tic douloureux, with the additional benefit of a much-reduced incidence of facial sensory loss when compared with differential thermal rhizotomy by a radiofrequency-induced lesion technique. Facial deafferentation is not mandatory for successful percutaneous treatment of tic douloureux.

Aged↗